Glenmark Pharmaceuticals Ltd. - Target Rs. 345

Glenmark Pharmaceuticals Ltd. (GPL) is a research-driven, global and integrated pharmaceutical company. Glenmark has re-organized its business model into two separate business units –Specialty business under the name of GPL and Generics business under the head of Glenmark Generics Limited (GGL), which is also GPL’s

subsidiary. Specialty division of Glenmark takes care of the new drug discovery and its branded generics business. The Generics business covers the pure (no brand name) generics and API’s (Active Pharmaceutical Ingredients). GPL is a leading player in the discovery of new molecules with eight molecules in various stages of clinical development. The company has twelve manufacturing facilities in four countries and has five R&D centers. GPL is focused in the areas of dermatology (skin related problems), inflammation (asthma etc.) and metabolic disorders (diabetes, obesity etc). It markets products in 70 countries across the globe including the regulated markets of the USA and Europe. Saldanha family is the promoter of GPL.